Besponsa
inotuzumab ozogamicin
Listed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- Strength
- .25 mg/mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Route
- Intravenous
- Class
- CD22-directed Immunoconjugate
What it contains
- Inotuzumab Ozogamicin .25 mg/mL
FDA record
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Drug class | CD22-directed Immunoconjugate |
| Approval route | BLA — biologic licence |
| NDC code | 0008-0100 |
| FDA application | BLA761040 |
| RxNorm concept | 1942954 |
| Package sizes listed | 1 |
| Marketed since | August 2017 |
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.